This database contains 231 studies, archived under the term: "ADLs/IADLs"
Click here to filter this large number of results.
Memantine in behavioral variant frontotemporal dementia: negative results
Vercelletto, Martine,
Boutoleau-Bretonnière, Claire,
Volteau, Christelle,
Puel, Michèle,
Auriacombe, Sophie,
Sarazin, Marie,
Michel, Bernard-François,
Couratier, Philippe,
Thomas-Antérion, Catherine,
Verpillat, Patrice,
Gabelle, Audrey,
Golfier, Véronique,
Cerato, Evelyne,
Lacomblez, Lucette
We tested the efficacy and tolerability of one-year treatment with memantine (10 mg bid) in behavioral variant frontotemporal dementia (bvFTD). BvFTD patients aged 45 to 75 years, with a Mini-Mental Status Examination (MMSE) score ≥19, were enrolled in a national, randomized, double-blind, placebo-controlled (DBPC), Phase II trial. The primary endpoint was the CIBIC-Plus (Clinician’s Interview-Based […]
Six-month walking program changes cognitive and ADL performance in patients with Alzheimer
Motor inactivity is typical in the later stages of Alzheimer’s disease although there is evidence that physical exercise can reduce depression and enhance performance of daily activities. The aim of this study was to determine whether a walking program could reduce the functional and cognitive decline of elderly nursing home residents in the later stages […]
EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study
Vellas, B.,
Sol, O.,
Snyder, P. J.,
Ousset, P. J.,
Haddad, R.,
Maurin, M.,
Lemarié, J. C.,
Désiré, L.,
Pando, M. P.
Background: EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer’s Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.; Methods: This pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, Phase IIA study was conducted in […]
The Indiana Alzheimer Disease Center’s Symposium on Mild Cognitive Impairment. Cognitive training in older adults: Lessons from the ACTIVE study
Unverzagt, Frederick,
Smith, David,
Rebok, George,
Marsiske, Michael,
Morris, John,
Jones, Richard,
Willis, Sherry,
Ball, Karlene,
King, Jonathan,
Koepke, Kathy,
Stoddard, Anne,
Tennstedt, Sharon
This paper is based on a presentation made during the Indiana Alzheimer Disease Center’s Symposium on Mild Cognitive Impairment on April 19, 2008. The results of the ACTIVE study (Advanced Cognitive Training for Independent and Vital Elderly) were presented at the symposium including review of previously published study findings. The ACTIVE study is a multicenter, […]
Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial
Teranishi, Mika,
Kurita, Masatake,
Nishino, Satoshi,
Takeyoshi, Kenji,
Numata, Yukio,
Sato, Tadahiro,
Tateno, Amane,
Okubo, Yoshiro
The descriptive term behavioral and psychological symptoms of dementia (BPSD) is used to cover a range of noncognitive disturbances including anxiety, depression, irritability, aggression, agitation, eating disorders, and inappropriate social or sexual behaviors. Behavioral and psychological symptoms of dementia are seen in about 90% of patients with dementia. We aimed to compare the efficacy and […]
Quality of life of nursing‐home residents with dementia subject to surveillance technology versus physical restraints: An explorative study
te Boekhorst, S.,
Depla, M. F. I. A.,
Francke, A. L.,
Twisk, J. W. R.,
Zwijsen, S. A.,
Hertogh, C. M. P. M.
Objective: As physical restraints should only be used in exceptional cases, there is an urgent need for alternatives to restraint use. Surveillance technology could be such an alternative. This study explored whether nursing-home residents with dementia subjected to surveillance technology had better quality of life scores for mood, behavioral and societal dimensions than residents with […]
Yokukansan treatment of chronic renal failure patients receiving hemodialysis, with behavioral and psychological symptoms of dementia: an open-label study
Sumiyoshi, Hidenori,
Mantani, Akio,
Nishiyama, Satoshi,
Fujiwaki, Soh,
Ohta, Shoichiro,
Masuda, Yoshikazu,
Tomita, Youhei,
Tarumoto, Naofumi,
Yamawaki, Shigeto
Objective: The efficacy and safety of yokukansan (YKS) for chronic renal failure (CRF) patients receiving hemodialysis with behavioral and psychological symptoms of dementia (BPSD) was evaluated.; Methods: Twelve CRF patients receiving hemodialysis with BPSD were recruited and 7.5 g of YKS powder was added to ongoing therapy with antipsychotics. Neuropsychiatric Inventory (NPI) criteria and Barthel […]